ABTT34
R$60.95
▼-1.18%
Stock
Abbott Laboratories
Official Company Name: Abbott Laboratories
Stock Symbol: ABTT34
Stock Market: B3 - Bovespa
Currency: Brazilian real - BRL
ABTT34 Stock Price - 1 Year Price Evolution & Moving Averages
1 Year Return
▲+29.82%
Daily closing prices, with moving averages and volumes - Brazilian real (BRL)
Moving averages:
- — EMA20
- — SMA50
- — SMA200
Abbott Categories
United States
languages
Healthcare
languages
Medical Devices
Healthcare
Medical Devices
Company Description
Abbott Laboratories is a multinational health care and medical devices company. Founded in 1888, Abbot manufactures medical devices including cardiovascular and neuromodulation devices, diagnostics products, branded generic medicines, and nutritional products for children and adults including Pedialyte, Similac, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip.
ABTT34 Stock Data
| Open | R$61.32 |
| High | R$63.42 |
| Low | R$60.95 |
| Close | R$60.95 |
| Volume | 27 |
| Previous Close | R$61.68 |
| 1-Day Change | -0.73 |
| 1-Year Change | 14.00 |
| Average Daily Volume | 538 |
| 52-Week High | R$67.61 |
| 52-Week Low | R$46.69 |
Ratios as of Jul. 4, 2025
| Beta | 0.74 |
| Trailing PE | 17.42 |
| Forward PE | 25.99 |
Disclaimer
All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!
Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.
Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).
Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.
Please conduct your own due diligence to verify insights.